Goncharov N V, Vasilyev K A, Kudryavtsev I V, Avdonin P P, Belinskaia D A, Stukova M A, Shamova O V, Avdonin P V
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia.
Research Institute of Hygiene, Occupational Pathology and Human Ecology, p/o Kuzmolovsky, Vsevolozhsky District, Leningrad Region, Russia.
J Evol Biochem Physiol. 2022;58(1):230-246. doi: 10.1134/S0022093022010203. Epub 2022 Mar 5.
The development of drugs for the therapy of COVID-19 is one of the main problems of modern physiology, biochemistry and pharmacology. Taking into account the available information on the participation of mast cells and the role of histamine in the pathogenesis of COVID-19, as well as information on the positive role of famotidine in the prevention and treatment of coronavirus infection, an experiment was carried out using famotidine in a mouse model. We used a type A/PR/8/34 (H1N1) virus adapted to mice. The antiviral drug oseltamivir (Tamiflu), which belongs to the group of neuraminidase inhibitors, was used as a reference drug. The use of famotidine in combination with oseltamivir can increase survival, improve the dynamics of animal weight, reduce the level of NKT cells and increase the level of naive T-helpers. Further studies of famotidine in vivo should be aimed at optimizing the regimen of drug use at a higher viral load, as well as with a longer use of famotidine.
开发用于治疗新型冠状病毒肺炎（COVID-19）的药物是现代生理学、生物化学和药理学的主要问题之一。考虑到有关肥大细胞参与及组胺在COVID-19发病机制中的作用的现有信息，以及法莫替丁在预防和治疗冠状病毒感染中的积极作用的信息，在小鼠模型中使用法莫替丁进行了一项实验。我们使用了适应小鼠的A/PR/8/34（H1N1）型病毒。属于神经氨酸酶抑制剂组的抗病毒药物奥司他韦（达菲）用作参考药物。法莫替丁与奥司他韦联合使用可提高存活率，改善动物体重动态，降低NKT细胞水平并提高初始T辅助细胞水平。对法莫替丁进行进一步的体内研究应旨在优化在更高病毒载量下的药物使用方案，以及延长法莫替丁的使用时间。
